SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Coronavirus disease-2019 (COVID-19) is primarily a respiratory disease, however, an increasing number of reports indicate that SARS-CoV-2 infection can also cause severe neurological manifestations, including precipitating cases of probable Parkinson’s disease. As microglial NLRP3 inflammasome activation is a major driver of neurodegeneration, here we interrogated whether SARS-CoV-2 can promote microglial NLRP3 inflammasome activation. Using SARS-CoV-2 infection of transgenic mice expressing human angiotensin-converting enzyme 2 (hACE2) as a COVID-19 pre-clinical model, we established the presence of virus in the brain together with microglial activation and NLRP3 inflammasome upregulation in comparison to uninfected mice. Next, utilising a model of human monocyte-derived microglia, we identified that SARS-CoV-2 isolates can bind and enter human microglia in the absence of viral replication. This interaction of virus and microglia directly induced robust inflammasome activation, even in the absence of another priming signal. Mechanistically, we demonstrated that purified SARS-CoV-2 spike glycoprotein activated the NLRP3 inflammasome in LPS-primed microglia, in a ACE2-dependent manner. Spike protein also could prime the inflammasome in microglia through NF-κB signalling, allowing for activation through either ATP, nigericin or α-synuclein. Notably, SARS-CoV-2 and spike protein-mediated microglial inflammasome activation was significantly enhanced in the presence of α-synuclein fibrils and was entirely ablated by NLRP3-inhibition. Finally, we demonstrate SARS-CoV-2 infected hACE2 mice treated orally post-infection with the NLRP3 inhibitory drug MCC950, have significantly reduced microglial inflammasome activation, and increased survival in comparison with untreated SARS-CoV-2 infected mice. These results support a possible mechanism of microglial innate immune activation by SARS-CoV-2, which could explain the increased vulnerability to developing neurological symptoms akin to Parkinson’s disease in COVID-19 infected individuals, and a potential therapeutic avenue for intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066 · cited 1×
“…microglial NLRP3 in fl ammasome activation occurs in vivo after SARS-CoV-2 infection; (ii) to determine whether increased NLRP3 in fl amma-some activation occurs in MDMi exposed to SARS-CoV-2 isolates; and (iii) to evaluate this activation in the presence of preformed fi brils of α - synuclein (Syn).”
BackgroundThe NLRP3 inflammasome: molecular activation and regulation to therapeutics
Swanson, K. V., Deng, M., & Ting, J. P.-Y. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0165-0 · Cited by 4,884
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Cell entry mechanisms of SARS-CoV-2
Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003138117 · Cited by 3,142
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Taquet, M., Geddes, J. R., Husain, M., Luciano, S., & Harrison, P. J. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00084-5 · Cited by 2,189 · cited 1×
“…microglial NLRP3 in fl ammasome activation occurs in vivo after SARS-CoV-2 infection; (ii) to determine whether increased NLRP3 in fl amma-some activation occurs in MDMi exposed to SARS-CoV-2 isolates; and (iii) to evaluate this activation in the presence of preformed fi brils of α - synuclein (Syn).”
BackgroundNervous system involvement after infection with COVID-19 and other coronaviruses
Wu, Y., Xu, X., Chen, Z., Duan, J., Hashimoto, K., Yang, L., Liu, C., & Yang, C. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.03.031 · Cited by 2,046
Multiorgan and Renal Tropism of SARS-CoV-2
Puelles, V. G., Lütgehetmann, M., Lindenmeyer, M. T., Sperhake, J. P., Wong, M. N., Allweiss, L., Chilla, S., Heinemann, A., Wanner, N., Liu, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2011400 · Cited by 1,775 · cited 1×
“…microglial NLRP3 in fl ammasome activation occurs in vivo after SARS-CoV-2 infection; (ii) to determine whether increased NLRP3 in fl amma-some activation occurs in MDMi exposed to SARS-CoV-2 isolates; and (iii) to evaluate this activation in the presence of preformed fi brils of α - synuclein (Syn).”
BackgroundMeinhardt, J., Radke, J., Dittmayer, C., Franz, J., Thomas, C., Mothes, R., Laue, M., Schneider, J., Brünink, S., Greuel, S., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00758-5 · Cited by 1,458
Cited by
Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathology
Aguado, J., Amarilla, A. A., Taherian Fard, A., Albornoz, E. A., Tyshkovskiy, A., Schwabenland, M., Chaggar, H. K., Modhiran, N., Gómez-Inclán, C., Javed, I., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00519-6 · Cited by 80
Self-citationRevisiting the Pathogenesis of X-Linked Adrenoleukodystrophy
Bougnères, P., & Le Stunff, C. (2025) · Genes · doi:10.3390/genes16050590 · Cited by 11
Metadata
- Authors
- Albornoz, E. A., Amarilla, A. A., Modhiran, N., Parker, S., Li, X. X., Wijesundara, D. K., Aguado, J., Zamora, A. P., McMillan, C. L. D., Liang, B., Peng, N. Y. G., Sng, J. D. J., Saima, F. T., Fung, J. N., Lee, J. D., Paramitha, D., Parry, R., Avumegah, M. S., Isaacs, A., Lo, M. W., Miranda-Chacon, Z., Bradshaw, D., Salinas-Rebolledo, C., Rajapakse, N. W., Wolvetang, E. J., Munro, T. P., Rojas-Fernandez, A., Young, P. R., Stacey, K. J., Khromykh, A. A., Chappell, K. J., Watterson, D., & Woodruff, T. M.
- Venue
- Molecular Psychiatry
- Published
- 2022-11-01
- Volume
- 28
- Issue
- 7
- Pages
- 2878-2893
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W4307846899
- Cited by
- 180
- References
- 21
- FWCI
- 10.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein. https://app.cochat.ai/papers/10.1038/s41380-022-01831-0
- The paper
- Albornoz, E. A., Amarilla, A. A., Modhiran, N., Parker, S., Li, X. X., Wijesundara, D. K., Aguado, J., Zamora, A. P., McMillan, C. L. D., Liang, B., Peng, N. Y. G., Sng, J. D. J., Saima, F. T., Fung, J. N., Lee, J. D., Paramitha, D., Parry, R., Avumegah, M. S., Isaacs, A., . . . Woodruff, T. M. (2023). SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein. Molecular Psychiatry. https://doi.org/10.1038/s41380-022-01831-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.